Best duration for postpartum remote blood pressure monitoring
HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring
NA · University of Minnesota · NCT07204756
This tests whether 2 weeks or 6 weeks of remote blood pressure monitoring after delivery works better for people who had hypertensive disorders of pregnancy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University of Minnesota (other) |
| Locations | 1 site (Minneapolis, Minnesota) |
| Trial ID | NCT07204756 on ClinicalTrials.gov |
What this trial studies
This randomized interventional study at the University of Minnesota enrolls postpartum patients with hypertensive disorders who are participating in the HOPE-BP remote monitoring program. At two weeks after delivery, eligible participants who are not on ongoing antihypertensive medication are randomized to either stop monitoring at 2 weeks or continue monitoring through 6 weeks. Clinical outcomes for the two monitoring durations are compared to determine differences in postpartum blood pressure control and related complications. The aim is to identify the monitoring length that best supports patient safety and efficient postpartum care at the institution.
Who should consider this trial
Good fit: Adults (18+) discharged after delivery from the University of Minnesota who enrolled in the HOPE-BP program and who are not taking antihypertensive medication at two weeks are ideal candidates.
Not a fit: People who remain on antihypertensive medications at two weeks, have medical comorbidities that preclude randomization, or who did not enroll in HOPE-BP are unlikely to benefit from this comparison.
Why it matters
Potential benefit: If successful, the results could identify the optimal monitoring length to reduce postpartum complications and unnecessary follow-up.
How similar studies have performed: Remote postpartum blood pressure monitoring programs have been widely adopted and vary between 2 and 6 weeks, but a randomized comparison of optimal duration is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * Discharged after delivery at University of Minnesota Medical Center * Enrolled into the HOPE-BP Program Exclusion Criteria: * Ongoing antihypertensive medication use at 2 weeks (time of randomization) * Have a medical comorbidity that would not be clinically appropriate to randomize * Patients opted out of clinical research
Where this trial is running
Minneapolis, Minnesota
- University of Minnesota — Minneapolis, Minnesota, United States (RECRUITING)
Study contacts
- Principal investigator: Bethany Sabol, MD MAS — University of Minnesota
- Study coordinator: Erin Linden
- Email: linde491@umn.edu
- Phone: 612-625-2273
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Postpartum, Hypertension, Hypertensive Disorder of Pregnancy